First NSCLC Patient Dosed With Trial Therapeutic
  (1/22/22)
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report. More >

Fund Triples Holding of Drug Repurposing Firm
Source: Streetwise Reports  (1/20/22)
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report. More >

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B
Source: Streetwise Reports  (1/19/22)
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met. More >

Derm Biopharma Named Top Growth Pick For 2022
  (1/18/22)
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report. More >

This Pharmaceutical Company Has a Brilliant Concept
Source: Penny Queen  (1/17/22)
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company. More >

Ph1 Trial Results of Dementia Drug Positive
  (1/12/22)
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report. More >

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial
Source: Streetwise Reports  (1/12/22)
Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study. More >

Biotech Co. Partners With Life Sciences Firms
  (1/11/22)
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report. More >

2022 to Be Catalyst Rich for Biopharma
  (1/10/22)
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report. More >

Enrollment Done for COVID-19 Drug Trial
  (1/10/22)
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report. More >

Co.'s samRNA Vaccines Protect Better Against COVID Variants
  (1/7/22)
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio. More >

AI Driven Drug Firm Partners With Merck
Source: Streetwise Reports  (1/7/22)
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creationâ„¢ platform and Bionic Proteinâ„¢ technologies. More >

Co. Partners to Test New Cancer Vaccines
  (1/6/22)
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigensâ„¢ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea. More >

Chen Lin's Top 6 Investment Ideas
Source: Streetwise Reports  (1/5/22)
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022. More >

New Muscular Dystrophy Drug Shows Promise
Source: Streetwise Reports  (1/5/22)
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial. More >

Co. Plans to Make 100M Rapid COVID Tests Monthly
  (1/5/22)
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22. More >

Lead Cancer Drug Gets Fast Tracked
Source: Streetwise Reports  (1/3/22)
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSAâ„¢ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment. More >

Analyst: Drug a 'Hidden Gem for 2022'
  (12/31/21)
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish." More >

Co. Looks To US For Help Fighting Strokes
Source: Streetwise Reports  (12/29/21)
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs. More >

Co. Still Compelling After Drug Trial Failure
  (12/29/21)
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report. More >

Co. Rated Outperform As Heart Failure Drug Nears Potential Approval
  (12/25/21)
"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report. More >

Analyst: Question Lingers Over Biotech’s Cell Therapy
  (12/23/21)
A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness.
More >

Coverage Initiated on Biopharma Co. After Turnaround Story
  (12/23/21)
"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report.
More >

Analyst Highlights Top Picks in Biotech for 2022
  (12/20/21)
Aldeyra Therapeutics, in the ophthalmology space, and SQZ Biotechnologies, in the cell therapy sector, have "advantages that their specific approaches allow," noted a BTIG report. More >

FDA Grants Approval for CNS-Focused Biopharma Firm's Bipolar Disorder Drug
Source: Streetwise Reports  (12/20/21)
Intra-Cellular Therapies Inc. shares traded 19% higher to a new 52-week high after the company reported the U.S. FDA has approved the use of its CAPLYTA® (lumateperone) for treatment of adults with bipolar depression. More >